title: A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients.
abstract: We retrospectively analyzed the data of 337 patients with cytogenetically normal (CN) acute myeloid leukemia (AML), aged ≤ 65 years (training set). A prognostic index score (PIS) was calculated by totaling the score derived from the regression coefficients of each clinical variable, significantly associated with prognosis by multivariate analysis. The variables that were independent prognostic factors for event-free survival (EFS) and overall survival (OS) in the training set were: age ≥ 50 years, secondary AML and white blood cell count (WBC) ≥ 20 × 10(9)/L. The patients of the training set were stratified into three groups: low-, intermediate- and high-risk. The median EFS was 25, 12 and 7 months in the low-, intermediate- and high-risk groups (p < 0.0001), respectively. The median OS was not reached in the low-risk group and was 19 and 10 months in the intermediate- and high-risk groups (p < 0.0001). This PIS was validated in a series of 193 patients with CN-AML. The median EFS was 66, 16, and 3 months (p < 0.0001) and the median OS was 66, 16, and 5 months in the three risk groups, respectively (p < 0.0001). This PIS may be useful for clinical decision-making in CN-AML and may be prospectively integrated with the newest biological markers which at present are not routinely assessed and need prognostic validation.
authors: Chair of Hematology, Unit of Blood Disease and Cell Therapy, Spedali Civili Hospital, Brescia, Italy. malagola@med.unibs.it
authors: Michele
authors: M
authors: Malagola
authors: Cristina
authors: C
authors: Skert
authors: Marco
authors: M
authors: Vignetti
authors: Alfonso
authors: A
authors: Piciocchi
authors: Giovanni
authors: G
authors: Martinelli
authors: Giuliana
authors: G
authors: Alimena
authors: Cristina
authors: C
authors: Mecucci
authors: Nicoletta
authors: N
authors: Testoni
authors: Ilaria
authors: I
authors: Iacobucci
authors: Marino
authors: M
authors: Clavio
authors: Marco
authors: M
authors: Gobbi
authors: Anna
authors: A
authors: Candoni
authors: Daniela
authors: D
authors: Damiani
authors: Monica
authors: M
authors: Bocchia
authors: Francesco
authors: F
authors: Lauria
authors: Alfonso
authors: A
authors: Zaccaria
authors: Patrizio
authors: P
authors: Mazza
authors: Giuseppe
authors: G
authors: Visani
authors: Annalisa
authors: A
authors: Peli
authors: Chiara
authors: C
authors: Colombi
authors: Valeria
authors: V
authors: Cancelli
authors: Marco
authors: M
authors: Mancini
authors: Robin
authors: R
authors: Foà
authors: Massimo
authors: M
authors: Martelli
authors: Nicola
authors: N
authors: Cantore
authors: Francesco
authors: F
authors: Di Raimondo
authors: Mario
authors: M
authors: Petrini
authors: Paolo
authors: P
authors: De Fabritiis
authors: Giuseppe
authors: G
authors: Fioritoni
authors: Francesco
authors: F
authors: Nobile
authors: Francesco
authors: F
authors: Fabbiano
authors: Giorgina
authors: G
authors: Specchia
authors: Michele
authors: M
authors: Baccarani
authors: Francesco
authors: F
authors: Lo Coco
authors: Sergio
authors: S
authors: Amadori
authors: Franco
authors: F
authors: Mandelli
authors: Domenico
authors: D
authors: Russo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult